Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)

被引:37
作者
Salvatore, Lisa [1 ]
Aprile, Giuseppe [2 ]
Arnoldi, Ermenegildo [3 ]
Aschele, Carlo [4 ]
Carnaghi, Carlo [5 ]
Cosimelli, Maurizio [6 ]
Maiello, Evaristo [7 ]
Normanno, Nicola [8 ]
Sciallero, Stefania [9 ]
Valvo, Francesca [10 ]
Beretta, Giordano D. [11 ]
机构
[1] Azienda Ospedaliero Univ Integrata Verona, Dept Oncol, Verona, Italy
[2] Osped San Bortolo, Dept Oncol, Vicenza, Italy
[3] Azienda Ospedaliera Papa Giovanni XXIII, Dept Oncol, Bergamo, Italy
[4] ASL5 Liguria, Dept Oncol, La Spezia, Italy
[5] Humanitas Canc Ctr, Dept Oncol, Rozzano, MI, Italy
[6] Ist Nazl Tumori Regina Elena, Dept Oncol Surg, Rome, Italy
[7] Osped Casa Sollievo Sofferenza, Dept Oncol, San Giovanni Rotondo, Puglia, Italy
[8] Ist Nazl Tumori Fondazione G Pascale IRCCS, Dept Cell Biol & Biotherapies, Naples, Italy
[9] Azienda Ospedaliera S Martino IRCCS, Dept Oncol, IST, Genoa, Italy
[10] Ctr Nazl Adroterapia, Dept Radiotherapy, Pavia, Italy
[11] Humanitas Gavazzeni, Dept Oncol, Bergamo, Italy
关键词
PHASE-III TRIAL; CAPECITABINE PLUS OXALIPLATIN; RESECTABLE LIVER METASTASES; 1ST-LINE TREATMENT; COMBINATION CHEMOTHERAPY; RANDOMIZED-TRIAL; OPEN-LABEL; ORAL FLUOROPYRIMIDINES; IMPROVES SURVIVAL; PANITUMUMAB PLUS;
D O I
10.1136/esmoopen-2016-000147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the past 15 years, the outcome for patients with metastatic colorectal cancer has substantially improved owing to the availability of new cytotoxic and biological agents along with many significant advances in molecular selection, the use of personalised therapy and locoregional treatment, a more widespread sharing of specific professional experiences (multidisciplinary teams with oncologists, surgeons, radiotherapists, radiologists, biologists and pathologists), and the adoption of patientcentred healthcare strategies. The Italian Medical Oncology Association (AIOM) has developed evidence-based recommendations to help oncologists and all professionals involved in the management of patients with metastatic colorectal cancer in their daily clinical practice.
引用
收藏
页数:11
相关论文
共 70 条
[1]  
AIOM, CONT SEGR
[2]   Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer [J].
Artale, Salvatore ;
Sartore-Bianchi, Andrea ;
Veronese, Silvio Marco ;
Gambi, Valentina ;
Sarnataro, Carolina Silvia ;
Gambacorta, Marcello ;
Lauricella, Calogero ;
Siena, Salvatore .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) :4217-4219
[3]   Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].
Bennouna, Jaafar ;
Sastre, Javier ;
Arnold, Dirk ;
Osterlund, Pia ;
Greil, Richard ;
Van Cutsem, Eric ;
von Moos, Roger ;
Maria Vieitez, Jose ;
Bouche, Olivier ;
Borg, Christophe ;
Steffens, Claus-Christoph ;
Alonso-Orduna, Vicente ;
Schlichting, Christoph ;
Reyes-Rivera, Irmarie ;
Bendahmane, Belguendouz ;
Andre, Thierry ;
Kubicka, Stefan .
LANCET ONCOLOGY, 2013, 14 (01) :29-37
[4]   Complete response of colorectal liver metastases after chemotherapy:: Does it mean cure? [J].
Benoist, Stephane ;
Brouquet, Antoine ;
Penna, Christophe ;
Julie, Catherine ;
El Hajjam, Mostafa ;
Chagnon, Sophie ;
Mitry, Emmanuel ;
Rougier, Philippe ;
Nordlinger, Bernard .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3939-3945
[5]   Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].
Bokemeyer, Carsten ;
Bondarenko, Igor ;
Makhson, Anatoly ;
Hartmann, Joerg T. ;
Aparicio, Jorge ;
de Braud, Filippo ;
Donea, Serban ;
Ludwig, Heinz ;
Schuch, Gunter ;
Stroh, Christopher ;
Loos, Anja H. ;
Zubel, Angela ;
Koralewski, Piotr .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671
[6]   Policy statement on multidisciplinary cancer care [J].
Borras, Josep M ;
Albreht, Tit ;
Audisio, Riccardo ;
Briers, Erik ;
Casali, Paolo ;
Esperou, Helene ;
Grube, Birgitte ;
Hamoir, Marc ;
Henning, Geoffrey ;
Kelly, Joan ;
Knox, Susan ;
Nabal, Maria ;
Pierotti, Marco ;
Lombardo, Claudio ;
van Harten, Wim ;
Poston, Graeme ;
Prades, Joan ;
Sant, Milena ;
Travado, Luzia ;
Valentini, Vincenzo ;
van de Velde, Cornelis ;
van den Bogaert, Saskia ;
van den Bulcke, Marc ;
van Hoof, Elke ;
van den Neucker, Ingrid ;
Wilson, Robin .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (03) :475-480
[7]   XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer [J].
Cassidy, J ;
Tabernero, J ;
Twelves, C ;
Brunet, R ;
Butts, C ;
Conroy, T ;
Debraud, F ;
Figer, A ;
Grossmann, J ;
Sawada, N ;
Schöffski, P ;
Sobrero, A ;
Van Cutsem, E ;
Diaz-Rubio, E .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2084-2091
[8]   Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer [J].
Cassidy, Jim ;
Clarke, Stephen ;
Diaz-Rubio, Eduardo ;
Scheithauer, Werner ;
Figer, Arie ;
Wong, Ralph ;
Koski, Sheryl ;
Lichinitser, Mikhail ;
Yang, Tsai-Shen ;
Rivera, Fernando ;
Couture, Felix ;
Sirzen, Florin ;
Saltz, Leonard .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :2006-2012
[9]   Platinum-sensitivity in metastatic colorectal cancer: Towards a definition [J].
Chibaudel, Benoist ;
Tournigand, Christophe ;
Bonnetain, Franck ;
Maindrault-Goebel, Frederique ;
Lledo, Gerard ;
Andre, Thierry ;
Larsen, Annette K. ;
Bengrine-Lefevre, Leila ;
Louvet, Christophe ;
de Gramont, Aimery .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (18) :3813-3820
[10]   Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study [J].
Chibaudel, Benoist ;
Maindrault-Goebel, Frederique ;
Lledo, Gerard ;
Mineur, Laurent ;
Andre, Thierry ;
Bennamoun, Mostepha ;
Mabro, May ;
Artru, Pascal ;
Carola, Elisabeth ;
Flesch, Michel ;
Dupuis, Olivier ;
Colin, Philippe ;
Larsen, Annette K. ;
Afchain, Pauline ;
Tournigand, Christophe ;
Louvet, Christophe ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5727-5733